Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 123 articles: HTML format

Single Articles

May 2026
1. STRAWSER CH, Chakraborty B, Michaud D, Chang CY, et al
   Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy.
   Clin Cancer Res. 2026 May 13. doi: 10.1158/1078-0432.CCR-25-0946.
   PubMed     Abstract available
   
   
   April 2026
2. AKAY M, Glendenning J, Tovey H, Tsai YT, et al
   A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer.
   Clin Cancer Res. 2026 Apr 28. doi: 10.1158/1078-0432.CCR-26-0041.
   PubMed     Abstract available
   
   
   
3. DESMEDT C, Nguyen HL, Richard F, Linn S, et al
   Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trial.
   Clin Cancer Res. 2026 Apr 17. doi: 10.1158/1078-0432.CCR-25-3808.
   PubMed     Abstract available
   
   
   
4. THURSBY SJ, Jin Z, Blum J, Gurau A, et al
   Epigenetic Instability-Based Metrics in Cell-Free DNA for Early Cancer Detection.
   Clin Cancer Res. 2026;32:1528-1539.
   PubMed     Abstract available
   
   
   
5. JHAVERI K, Eli LD, Hurvitz SA, Brufsky A, et al
   Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.
   Clin Cancer Res. 2026 Apr 6. doi: 10.1158/1078-0432.CCR-25-4135.
   PubMed     Abstract available
   
   
   March 2026
6. BHARADWAJ S, Corredor G, Al-Shakhshir H, Medina S, et al
   Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B41 Clinical Trial Validation.
   Clin Cancer Res. 2026 Mar 31. doi: 10.1158/1078-0432.CCR-25-4185.
   PubMed     Abstract available
   
   
   
7. POISSONNIER A, Rugo HS, Horton W, Kim T, et al
   CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors.
   Clin Cancer Res. 2026 Mar 27. doi: 10.1158/1078-0432.CCR-25-4236.
   PubMed     Abstract available
   
   
   
8. SALGADO R, Kok M
   Immunity, age, and luminal breast cancer: understanding the Holy Trinity.
   Clin Cancer Res. 2026 Mar 19. doi: 10.1158/1078-0432.CCR-25-4035.
   PubMed     Abstract available
   
   
   
9. CARLETON N, Chang AC, Chen F, Puhalla SL, et al
   Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.
   Clin Cancer Res. 2026 Mar 19:OF1-OF11. doi: 10.1158/1078-0432.CCR-25-4079.
   PubMed     Abstract available
   
   
   February 2026
10. ROSESHTER T, Klemantovich A, Lafleur J, Lan C, et al
    Clinical Validation of Digital PCR-based ctDNA detection for risk stratification in residual triple negative breast cancer: TRICIA trial results.
    Clin Cancer Res. 2026 Feb 9. doi: 10.1158/1078-0432.CCR-25-2234.
    PubMed     Abstract available
    
    
    
11. GRIGUOLO G, Bottosso M, Landa G, Bonomi G, et al
    Proactive brain screening using contrast-enhanced brain CT scans in HER2+ metastatic breast cancer.
    Clin Cancer Res. 2026 Feb 9. doi: 10.1158/1078-0432.CCR-25-3557.
    PubMed     Abstract available
    
    
    
12. NIRAVATH P, Uzair I, Sun K, Mai H, et al
    A phase II study of docetaxel and pembrolizumab plus Interleukin-12 gene therapy in non-metastatic, anthracycline-refractory triple negative breast cancer (INTEGRAL).
    Clin Cancer Res. 2026 Feb 9. doi: 10.1158/1078-0432.CCR-25-2649.
    PubMed     Abstract available
    
    
    
13. OLIVEIRA M, Ciruelos E, Villacampa G, Morales S, et al
    Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.
    Clin Cancer Res. 2026;32:468-478.
    PubMed     Abstract available
    
    
    
14. VOORTHUIS RAB, Oliveira M, van Rossum AGJ, de Boo LW, et al
    PI3K inhibition in combination with tamoxifen in patients with metastatic HR+/HER2- breast cancer: clinical and circulating tumor DNA results.
    Clin Cancer Res. 2026 Feb 3. doi: 10.1158/1078-0432.CCR-25-2833.
    PubMed     Abstract available
    
    
    January 2026
15. RAMPA DR, Seo M, Ogata N, Yang Z, et al
    Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer.
    Clin Cancer Res. 2026 Jan 27. doi: 10.1158/1078-0432.CCR-25-3321.
    PubMed     Abstract available
    
    
    
16. BIANCHINI G, Malorni L, Caputo R, Zambelli A, et al
    Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trial.
    Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-0650.
    PubMed     Abstract available
    
    
    
17. CONTE B, Braso-Maristany F, Pascual T, Hernando C, et al
    Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes.
    Clin Cancer Res. 2026 Jan 22. doi: 10.1158/1078-0432.CCR-25-2570.
    PubMed     Abstract available
    
    
    
18. HACHEY J, Viray TD, Carrasco SE, Carter LM, et al
    Exploring the 89 Zr/ 177 Lu Theranostic Pairing with an Extracellular Matrix Targeted Radiopharmaceutical Against Triple Negative Breast Cancer.
    Clin Cancer Res. 2026 Jan 15. doi: 10.1158/1078-0432.CCR-25-3354.
    PubMed     Abstract available
    
    
    
19. JHAVERI K, Loi S, Hamilton E, Schmid P, et al
    DESTINY-Breast08: a phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancer.
    Clin Cancer Res. 2026 Jan 8. doi: 10.1158/1078-0432.CCR-25-0874.
    PubMed     Abstract available
    
    
    
20. JURIC D, Song K, Johnson RM, Accordino MK, et al
    PI3Kalpha Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
    Clin Cancer Res. 2026;32:56-75.
    PubMed     Abstract available
    
    
    December 2025
21. BIAGIONI C, Fimereli D, Irrthum A, Guerrero-Zotano A, et al
    Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01).
    Clin Cancer Res. 2025 Dec 22. doi: 10.1158/1078-0432.CCR-25-2707.
    PubMed     Abstract available
    
    
    
22. RUGO HS, Cescon DW, Robson ME, Im SA, et al
    KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy.
    Clin Cancer Res. 2025 Dec 17. doi: 10.1158/1078-0432.CCR-25-1818.
    PubMed     Abstract available
    
    
    
23. SANDOVAL JL, Kiavue N, Djerroudi L, Jacot W, et al
    Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial.
    Clin Cancer Res. 2025;31:5178-5187.
    PubMed     Abstract available
    
    
    
24. MARTIN M, Guerrero-Zotano AL, Perez-Lopez ME, Ruiz-Borrego M, et al
    Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.
    Clin Cancer Res. 2025 Dec 12. doi: 10.1158/1078-0432.CCR-25-2435.
    PubMed     Abstract available
    
    
    
25. CIRUELOS E, Pascual T, Villacampa G, Pernas S, et al
    Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial.
    Clin Cancer Res. 2025 Dec 3. doi: 10.1158/1078-0432.CCR-25-2882.
    PubMed     Abstract available
    
    
    
26. LYNCE F, Graham N, Kochupurakkal BS, Nguyen H, et al
    A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer.
    Clin Cancer Res. 2025 Dec 3. doi: 10.1158/1078-0432.CCR-25-0571.
    PubMed     Abstract available
    
    
    
27. SANFELIU E, Martinez-Romero A, Marin-Aguilera M, Cobo S, et al
    Associations of the HER2DX Genomic Test with Biological and Pathological Features in HER2-positive Breast Cancer.
    Clin Cancer Res. 2025 Dec 1. doi: 10.1158/1078-0432.CCR-25-3123.
    PubMed     Abstract available
    
    
    
28. CORTES J, Priego A, Garralda E, Rojas K, et al
    A First-in-Class mAb (BI-1607) Targeting FcgammaRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.
    Clin Cancer Res. 2025;31:4953-4963.
    PubMed     Abstract available
    
    
    
29. DAHMER TIECHER R, Schram AM
    Tumor-Agnostic AKT Inhibition: Is It Time to AKT?
    Clin Cancer Res. 2025;31:4863-4865.
    PubMed     Abstract available
    
    
    November 2025
30. RUGO HS, Kaklamani V, McArthur H, Wander SA, et al
    Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Nov 14. doi: 10.1158/1078-0432.CCR-25-3040.
    PubMed     Abstract available
    
    
    
31. HOWARD FM, Fasching PA, Santa-Maria CA, Lim E, et al
    Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data.
    Clin Cancer Res. 2025 Nov 10. doi: 10.1158/1078-0432.CCR-25-1946.
    PubMed     Abstract available
    
    
    
32. KNUTSON KL, Abu-Fares H, Keating P, Block MS, et al
    A phase II trial to evaluate the safety and immunogenicity of two doses of a folate receptor alpha vaccine in patients with triple negative breast cancer.
    Clin Cancer Res. 2025 Nov 10. doi: 10.1158/1078-0432.CCR-25-2763.
    PubMed     Abstract available
    
    
    
33. LLOYD MR, Weipert CM, Ali A, Solomon SR, et al
    Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer.
    Clin Cancer Res. 2025 Nov 7. doi: 10.1158/1078-0432.CCR-25-3033.
    PubMed     Abstract available
    
    
    
34. GRAESER M, Gluz O, Schmid P, Jozwiak K, et al
    Multiomic factor analysis for pathologic complete response after pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: WSG-Keyriched-1 trial.
    Clin Cancer Res. 2025 Nov 3. doi: 10.1158/1078-0432.CCR-25-1923.
    PubMed     Abstract available
    
    
    
35. DAVIS AA, Jaeger E, Hagemann IS, Behdad A, et al
    Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity.
    Clin Cancer Res. 2025;31:4485-4494.
    PubMed     Abstract available
    
    
    October 2025
36. BROWNE IM, Pascual J, Cutts RJ, Kingston B, et al
    The Prognostic and Predictive Impact of Circulating Tumour DNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial.
    Clin Cancer Res. 2025 Oct 29. doi: 10.1158/1078-0432.CCR-24-0651.
    PubMed     Abstract available
    
    
    
37. TESCH ME, Zheng Y, Guzman-Arocho YD, Collins LC, et al
    Association of tumor-infiltrating lymphocyte subtypes with clinical characteristics and prognosis in young women with hormone receptor-positive breast cancer.
    Clin Cancer Res. 2025 Oct 21. doi: 10.1158/1078-0432.CCR-25-0948.
    PubMed     Abstract available
    
    
    
38. LIU R, Wang X, Branigan TB, Griffin D, et al
    BET bromodomain inhibition reverses CDK4/6 inhibitor resistance in estrogen receptor-positive breast cancer via induction of miR-34a-5p.
    Clin Cancer Res. 2025 Oct 7. doi: 10.1158/1078-0432.CCR-25-1406.
    PubMed     Abstract available
    
    
    
39. MURDTER TE, Schroth W, Goetz MP, Tremmel R, et al
    Supplementation of Tamoxifen with low-dose Endoxifen in breast cancer patients with impaired tamoxifen metabolism (TAMENDOX): a randomized controlled phase 1/2 trial.
    Clin Cancer Res. 2025 Oct 2. doi: 10.1158/1078-0432.CCR-25-2103.
    PubMed     Abstract available
    
    
    September 2025
40. GUIU S, Balmana J, Lemercier P, Follana P, et al
    Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER+/HER2- breast cancer and selected genomic alterations: results of the DOLAF trial.
    Clin Cancer Res. 2025 Sep 23. doi: 10.1158/1078-0432.CCR-24-4221.
    PubMed     Abstract available
    
    
    
41. REED SC, Potts CR, Luo L, Davidson BA, et al
    Clonal hematopoiesis of indeterminate potential influences breast cancer outcomes in a genotype-specific manner.
    Clin Cancer Res. 2025 Sep 19. doi: 10.1158/1078-0432.CCR-25-2009.
    PubMed     Abstract available
    
    
    
42. KOLBERG HC, Schumacher J, Erber R, Braun M, et al
    Atezolizumab monotherapy window preceding combined neoadjuvant chemo- and immune therapy in triple negative breast cancer (TNBC) - the neoMono trial.
    Clin Cancer Res. 2025 Sep 11. doi: 10.1158/1078-0432.CCR-25-1288.
    PubMed     Abstract available
    
    
    
43. MIGLIETTA F, De Graaf M, Vernieri C, Piacentini F, et al
    Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial.
    Clin Cancer Res. 2025 Sep 4. doi: 10.1158/1078-0432.CCR-25-1796.
    PubMed     Abstract available
    
    
    
44. PETRICOIN EF, Wolf DM, Yau C, Wulfkuhle JD, et al
    Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer.
    Clin Cancer Res. 2025 Sep 4:OF1-OF11. doi: 10.1158/1078-0432.CCR-25-0553.
    PubMed     Abstract available
    
    
    August 2025
45. ROYCE M, Shah M, Zhang L, Cheng J, et al
    FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer.
    Clin Cancer Res. 2025 Aug 27:10.1158/1078-0432.CCR-25-1388.
    PubMed     Abstract available
    
    
    
46. PATEL RJS, Wu C, Stowers CE, Mohamed RM, et al
    MRI-based mathematical modeling to predict the response of I-SPY 2 breast cancer patients to neoadjuvant therapy.
    Clin Cancer Res. 2025 Aug 26. doi: 10.1158/1078-0432.CCR-25-0668.
    PubMed     Abstract available
    
    
    
47. GERRATANA L, Reduzzi C, Ren Y, Jeselsohn R, et al
    Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study.
    Clin Cancer Res. 2025 Aug 25. doi: 10.1158/1078-0432.CCR-25-0327.
    PubMed     Abstract available
    
    
    
48. JEON SH, Suh KJ, Jung S, Jeon M, et al
    Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancer.
    Clin Cancer Res. 2025 Aug 20. doi: 10.1158/1078-0432.CCR-24-3283.
    PubMed     Abstract available
    
    
    
49. BAIRD RD, Bermejo de Las Heras B, Ruiz-Borrego M, Vaklavas C, et al
    Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-1198.
    PubMed     Abstract available
    
    
    
50. KJELDSTED E, Ammitzboll G, Laenkholm AV, Rasic D, et al
    Effects of supervised exercise during neoadjuvant chemotherapy on tumour response in patients with breast cancer (Neo-train): a randomised controlled trial.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0416.
    PubMed     Abstract available
    
    
    July 2025
51. WESOLOWSKI R, Rugo HS, Specht JM, Han H, et al
    Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer.
    Clin Cancer Res. 2025 Jul 25. doi: 10.1158/1078-0432.CCR-25-0992.
    PubMed     Abstract available
    
    
    
52. LICATA L, Mariani M, Viale G, Dent R, et al
    Timing of Recurrence After Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer.
    Clin Cancer Res. 2025 Jul 21. doi: 10.1158/1078-0432.CCR-25-1478.
    PubMed     Abstract available
    
    
    
53. GONZALEZ-ERICSSON PI, Unni N, Jhaveri K, Stringer-Reasor E, et al
    Phase Ib Trial of Fulvestrant, Palbociclib and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Jul 8. doi: 10.1158/1078-0432.CCR-24-3803.
    PubMed     Abstract available
    
    
    
54. KIMBUNG S, Veerla S, Muhammad K, Ehinger A, et al
    Global Transcriptional Complexity of Estrogen Receptor-Low Positive Breast Cancers in the Prospective Swedish Population-Based SCAN-B Cohort.
    Clin Cancer Res. 2025;31:2695-2709.
    PubMed     Abstract available
    
    
    June 2025
55. ROJO F, Taylor CR, Barrios C, Torrecillas L, et al
    FOXC1 expression predicts capecitabine efficacy in triple-negative breast cancer patients from the GEICAM_CIBOMA trial.
    Clin Cancer Res. 2025 Jun 26. doi: 10.1158/1078-0432.CCR-25-0338.
    PubMed     Abstract available
    
    
    
56. MCTIERNAN A
    In Motion: Experimental Evidence on Exercise and Breast Cancer in Women and Mice.
    Clin Cancer Res. 2025 Jun 18. doi: 10.1158/1078-0432.CCR-25-1313.
    PubMed     Abstract available
    
    
    
57. DE GROOT AF, Cohen D, Heijns JB, Mandigers CMPW, et al
    Ribociclib-letrozole combination as an alternative for neoadjuvant chemotherapy in selected post-menopausal patients with luminal breast cancer (BOOG 2017-01).
    Clin Cancer Res. 2025 Jun 10. doi: 10.1158/1078-0432.CCR-24-3402.
    PubMed     Abstract available
    
    
    May 2025
58. PRIEDIGKEIT N, Harrison B, Shue R, Hughes ME, et al
    Clinicogenomic characterization of inflammatory breast cancer.
    Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-24-2081.
    PubMed     Abstract available
    
    
    
59. LI Y, Zhang T, Korkaya H, Liu S, et al
    Correction: Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells.
    Clin Cancer Res. 2025;31:2062.
    PubMed    
    
    
    
60. GWIN WR 3RD, Hurvitz SA
    TOP1 Priority: Advancing Biomarker-Driven Patient Selection for the Use of ADCs.
    Clin Cancer Res. 2025;31:1824-1826.
    PubMed     Abstract available
    
    
    
61. CHUMSRI S, Larson JJ, Liu E, Tenner KS, et al
    Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer.
    Clin Cancer Res. 2025;31:1885-1893.
    PubMed     Abstract available
    
    
    
62. FASCHING PA, Schmatloch S, Hauke J, Rey J, et al
    Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.
    Clin Cancer Res. 2025;31:1596-1604.
    PubMed     Abstract available
    
    
    April 2025
63. CLARK AS, Zhao F, Klein P, Montero AJ, et al
    A Phase II Randomized Study of Paclitaxel alone or combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor Positive Breast Cancer: the BRACELET-01/PrE0113 study.
    Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-2701.
    PubMed     Abstract available
    
    
    
64. JOHANSSON H, Macis D, Oliva M, Puntoni M, et al
    Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial.
    Clin Cancer Res. 2025 Apr 28:OF1-OF6. doi: 10.1158/1078-0432.CCR-24-2987.
    PubMed     Abstract available
    
    
    
65. JIAO D, Qiao J, Sun X, Wang C, et al
    Application of Neoadjuvant Docetaxel Plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial.
    Clin Cancer Res. 2025 Apr 21. doi: 10.1158/1078-0432.CCR-25-0289.
    PubMed     Abstract available
    
    
    
66. YAP TA, Goldman JW, Vinayak S, Tomova A, et al
    First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.
    Clin Cancer Res. 2025 Apr 17. doi: 10.1158/1078-0432.CCR-24-2740.
    PubMed     Abstract available
    
    
    
67. GOUGH M, Kwah KKX, Khan T, Ghosh S, et al
    Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast Cancers.
    Clin Cancer Res. 2025;31:1504-1519.
    PubMed     Abstract available
    
    
    
68. JONES LW, Lavery JA, Tsai BL, Moskowitz CS, et al
    A Co-Clinical Trial of Exercise Therapy in Breast Cancer Prevention.
    Clin Cancer Res. 2025 Apr 4. doi: 10.1158/1078-0432.CCR-24-4298.
    PubMed     Abstract available
    
    
    
69. LIU J, Song C, Yang Y, Wang X, et al
    Safety and Efficacy of KN046 in combination with KN026 in Patients with advanced HER2-positive Breast Cancer: a Phase II Trial.
    Clin Cancer Res. 2025 Apr 4. doi: 10.1158/1078-0432.CCR-24-3888.
    PubMed     Abstract available
    
    
    March 2025
70. JILDERDA MF, Zhang Y, Rebattu V, Salunga R, et al
    Identification of Early-Stage Breast Cancer with Minimal Risk of Recurrence by Breast Cancer Index.
    Clin Cancer Res. 2025 Mar 27. doi: 10.1158/1078-0432.CCR-24-3836.
    PubMed     Abstract available
    
    
    
71. ADEMUYIWA FO, Ma CX, Weilbaecher K, Suresh R, et al
    Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple negative breast cancer.
    Clin Cancer Res. 2025 Mar 21. doi: 10.1158/1078-0432.CCR-24-3145.
    PubMed     Abstract available
    
    
    
72. JANNI W, Friedl TWP, Yab TC, Bidard FC, et al
    Clinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis.
    Clin Cancer Res. 2025 Mar 18. doi: 10.1158/1078-0432.CCR-24-3108.
    PubMed     Abstract available
    
    
    February 2025
73. FASCHING PA, Slamon D, Nowecki Z, Kukielka-Budny B, et al
    Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial.
    Clin Cancer Res. 2025 Feb 28. doi: 10.1158/1078-0432.CCR-24-1724.
    PubMed     Abstract available
    
    
    
74. LIN CA, Chica-Parrado MR, Unni N, Jaeger E, et al
    ESR1 Y537S and D538G mutations drive resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer.
    Clin Cancer Res. 2025 Feb 25. doi: 10.1158/1078-0432.CCR-24-2307.
    PubMed     Abstract available
    
    
    
75. POUGOUE KETCHEMEN J, Njotu FN, Babeker H, Monzer A, et al
    Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody-Drug Radioconjugate.
    Clin Cancer Res. 2025;31:685-696.
    PubMed     Abstract available
    
    
    
76. GOEL S, Jovanovic B, Chu X, Hughes M, et al
    A phase II study of abemaciclib for patients with retinoblastoma-positive, triple-negative metastatic breast cancer.
    Clin Cancer Res. 2025 Feb 5. doi: 10.1158/1078-0432.CCR-24-2647.
    PubMed     Abstract available
    
    
    
77. DRAKE RJG, Landen AH, Holmberg E, Stenmark Tullberg A, et al
    Endothelial cell pY397-FAK expression predicts risk of breast cancer recurrences after radiotherapy in SweBCG91-RT cohort.
    Clin Cancer Res. 2025 Feb 5. doi: 10.1158/1078-0432.CCR-24-2939.
    PubMed     Abstract available
    
    
    
78. KOBOLD S
    RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
    Clin Cancer Res. 2025;31:437-438.
    PubMed     Abstract available
    
    
    
79. JAEGER-RUCKSTUHL CA, Specht JM, Voutsinas JM, MacMillan HR, et al
    Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.
    Clin Cancer Res. 2025;31:503-514.
    PubMed     Abstract available
    
    
    January 2025
80. SOOD R, Niemierko A, Ryan L, Spring L, et al
    Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Jan 27. doi: 10.1158/1078-0432.CCR-24-2825.
    PubMed     Abstract available
    
    
    
81. GOUDA MA, Gonugunta A, Dumbrava EE, Yap TA, et al
    Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Jan 22. doi: 10.1158/1078-0432.CCR-24-3468.
    PubMed     Abstract available
    
    
    
82. RIOS-HOYO A, Xiong K, Dai J, Yau C, et al
    Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.
    Clin Cancer Res. 2025;31:403-413.
    PubMed     Abstract available
    
    
    
83. VIDAL M, Falato C, Pascual T, Sanchez-Bayona R, et al
    Elacestrant in women with estrogen receptor-positive and HER2-negative early breast cancer: results from the preoperative window-of-opportunity ELIPSE trial.
    Clin Cancer Res. 2025 Jan 16. doi: 10.1158/1078-0432.CCR-24-2460.
    PubMed     Abstract available
    
    
    
84. ELLIOTT MJ, Howarth K, Main S, Fuentes Antras J, et al
    Ultrasensitive Detection and Monitoring of Circulating Tumor DNA using Structural Variants in Early-Stage Breast Cancer.
    Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-3472.
    PubMed     Abstract available
    
    
    
85. MAURYA SK, Jaramillo-Gomez JA, Rehman AU, Gautam SK, et al
    Mucin5AC promotes breast cancer brain metastasis through cMET/CD44v6.
    Clin Cancer Res. 2025 Jan 6. doi: 10.1158/1078-0432.CCR-24-1977.
    PubMed     Abstract available
    
    
    
86. HUANG H, Couch RE, Karam R, Hu C, et al
    Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast.
    Clin Cancer Res. 2025;31:130-138.
    PubMed     Abstract available
    
    
    
87. ABELMAN RO, Wu B, Barnes H, Medford A, et al
    TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Jan 2. doi: 10.1158/1078-0432.CCR-24-2771.
    PubMed     Abstract available
    
    
    December 2024
88. VILLACAMPA G, Llop-Guevara A, Filmann N, Herencia A, et al
    RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-3148.
    PubMed     Abstract available
    
    
    
89. HAMILTON E, Galsky MD, Ochsenreither S, Del Conte G, et al
    Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
    Clin Cancer Res. 2024;30:5548-5558.
    PubMed     Abstract available
    
    
    November 2024
90. MERIC-BERNSTAM F, Yuca E, Evans KW, Zhao M, et al
    Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models.
    Clin Cancer Res. 2024 Nov 25. doi: 10.1158/1078-0432.CCR-24-1948.
    PubMed     Abstract available
    
    
    
91. FERRARIO C, Mackey J, Gelmon KA, Levasseur N, et al
    Phase Ib pharmacodynamic study of the MNK inhibitor Tomivosertib (eFT508) combined with paclitaxel in patients with refractory metastatic breast cancer.
    Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-0841.
    PubMed     Abstract available
    
    
    
92. ANAMPA JD, Flynn DL, Leary C, Oh S, et al
    Phase Ib clinical and pharmacodynamic study of the TIE2 kinase inhibitor rebastinib with paclitaxel or eribulin in HER2-negative metastatic breast cancer.
    Clin Cancer Res. 2024 Nov 12. doi: 10.1158/1078-0432.CCR-24-2464.
    PubMed     Abstract available
    
    
    October 2024
93. REDITI M, Fimereli D, Mileva M, Wimana Z, et al
    Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis of the ZEPHIR clinical trial.
    Clin Cancer Res. 2024 Oct 29. doi: 10.1158/1078-0432.CCR-24-1007.
    PubMed     Abstract available
    
    
    
94. NEVEN P, Stahl N, Vidal M, Martin M, et al
    A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from EMBER-2 Study.
    Clin Cancer Res. 2024 Oct 8. doi: 10.1158/1078-0432.CCR-24-2113.
    PubMed     Abstract available
    
    
    
95. BARDIA A, Cortes J, Bidard FC, Neven P, et al
    Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
    Clin Cancer Res. 2024;30:4299-4309.
    PubMed     Abstract available
    
    
    September 2024
96. DUGO M, Huang CS, Egle D, Bermejo B, et al
    The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2024 Sep 23:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0149.
    PubMed     Abstract available
    
    
    
97. QUINTELA-FANDINO M, Bermejo B, Zamora E, Moreno F, et al
    High mechanical conditioning by tumor extracellular matrix stiffness is a predictive biomarker for anti-fibrotic therapy in HER2-negative breast cancer.
    Clin Cancer Res. 2024 Sep 16. doi: 10.1158/1078-0432.CCR-24-1518.
    PubMed     Abstract available
    
    
    
98. GIORDANO A, Kumthekar PU, Jin Q, Binboga Kurt B, et al
    A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer.
    Clin Cancer Res. 2024 Sep 3. doi: 10.1158/1078-0432.CCR-24-1161.
    PubMed     Abstract available
    
    
    August 2024
99. ROJO F, Najera L, Lirola J, Jimenez J, et al
    Editor's Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer That Correlates with Pathologic Grade and Prognosis.
    Clin Cancer Res. 2024;30:3641.
    PubMed    
    
    
    
100. GILLMORE R, Xue SA, Holler A, Kaeda J, et al
     Editor's Note: Detection of Wilms' Tumor Antigen-Specific CTL in Tumor-Draining Lymph Nodes of Patients with Early Breast Cancer.
     Clin Cancer Res. 2024;30:3642.
     PubMed    
     
     
     
101. JOVANOVIC B, Church SE, Gorman KM, North K, et al
     Integrative multi-omic profiling of triple-negative breast cancer for identifying suitable therapies.
     Clin Cancer Res. 2024 Aug 13. doi: 10.1158/1078-0432.CCR-23-1242.
     PubMed     Abstract available
     
     
     
102. PIFFOUX M, Jacquemin J, Petera M, Durand S, et al
     Metabolomic prediction of breast cancer treatment induced neurological and metabolic toxicities.
     Clin Cancer Res. 2024 Aug 6. doi: 10.1158/1078-0432.CCR-24-0195.
     PubMed     Abstract available
     
     
     July 2024
103. DENT RA, Kim SB, Oliveira M, Barrios C, et al
     Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.
     Clin Cancer Res. 2024 Jul 26. doi: 10.1158/1078-0432.CCR-24-0465.
     PubMed     Abstract available
     
     
     
104. SUN X, Kennedy LC, Gonzalez-Ericsson PI, Sanchez V, et al
     Associations of immune checkpoint predictive biomarkers MHC-I and MHC-II with clinical and molecular features in a diverse breast cancer cohort.
     Clin Cancer Res. 2024 Jul 15. doi: 10.1158/1078-0432.CCR-24-1286.
     PubMed     Abstract available
     
     
     
105. LLOMBART-CUSSAC A, Perez-Garcia J, Braso-Maristany F, Pare L, et al
     HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial.
     Clin Cancer Res. 2024 Jul 12. doi: 10.1158/1078-0432.CCR-24-0464.
     PubMed     Abstract available
     
     
     
106. STEARNS V, Jegede OA, Chang VT, Skaar TC, et al
     A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.
     Clin Cancer Res. 2024;30:2709-2718.
     PubMed     Abstract available
     
     
     June 2024
107. SCHMIESTER L, Braso-Maristany F, Gonzalez-Farre B, Pascual T, et al
     Computational model predicts patient outcomes in Luminal B breast cancer treated with endocrine therapy and CDK4/6 inhibition.
     Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-24-0244.
     PubMed     Abstract available
     
     
     
108. JANK P, Karn T, van Mackelenbergh M, Lindner J, et al
     An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
     Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-24-0459.
     PubMed     Abstract available
     
     
     
109. ZHANG Q, Cai Z, Gerratana L, Davis AA, et al
     Early evaluation of risk stratification and clinical outcomes for patients with advanced breast cancer through combined monitoring of baseline circulating tumor cells and DNA.
     Clin Cancer Res. 2024 Jun 3. doi: 10.1158/1078-0432.CCR-24-0535.
     PubMed     Abstract available
     
     
     
110. MAKHLIN I, Demissei BG, D'Agostino R, Hundley WG, et al
     Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial.
     Clin Cancer Res. 2024;30:2370-2376.
     PubMed     Abstract available
     
     
     May 2024
111. GOUGH SM, Flanagan JJ, Teh J, Andreoli M, et al
     Oral estrogen receptor PROTAC(R) vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models.
     Clin Cancer Res. 2024 May 31. doi: 10.1158/1078-0432.CCR-23-3465.
     PubMed     Abstract available
     
     
     
112. CHEUNG A, Chenoweth AM, Johansson A, Laddach R, et al
     Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth.
     Clin Cancer Res. 2024 May 21. doi: 10.1158/1078-0432.CCR-23-3110.
     PubMed     Abstract available
     
     
     
113. HADDAD TC, Suman VJ, Giridhar KV, Sideras K, et al
     Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early-stage breast cancer: A prospective trial.
     Clin Cancer Res. 2024 May 16. doi: 10.1158/1078-0432.CCR-24-0341.
     PubMed     Abstract available
     
     
     
114. WANDER SA, Bardia A
     Cracking the Genomic Code of CDK4/6 Inhibitor Resistance.
     Clin Cancer Res. 2024;30:2008-2010.
     PubMed     Abstract available
     
     
     
115. BARDIA A, Sun S, Thimmiah N, Coates JT, et al
     Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients.
     Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-24-0428.
     PubMed     Abstract available
     
     
     April 2024
116. BOTTOSSO M, Miglietta F, Vernaci GM, Giarratano T, et al
     Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer.
     Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020.
     PubMed     Abstract available
     
     
     
117. IWASE T, Cohen EN, Gao H, Alexander A, et al
     Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy.
     Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2947.
     PubMed     Abstract available
     
     
     
118. MOYER CL, Lanier A, Qian J, Coleman D, et al
     IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy.
     Clin Cancer Res. 2024 Apr 5. doi: 10.1158/1078-0432.CCR-23-3839.
     PubMed     Abstract available
     
     
     
119. HAN YJ, Liu S, Hardeman A, Rajagopal PS, et al
     The VEGF-Hypoxia Signature is Upregulated in Basal like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer.
     Clin Cancer Res. 2024 Apr 2. doi: 10.1158/1078-0432.CCR-23-1526.
     PubMed     Abstract available
     
     
     
120. CONNOLLY RM, Wang V, Hyman DM, Grivas P, et al
     Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
     Clin Cancer Res. 2024;30:1273-1280.
     PubMed     Abstract available
     
     
     March 2024
121. MAGBANUA MJM, Ahmed Z, Sayaman RW, Brown Swigart L, et al
     Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
     Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-23-2928.
     PubMed     Abstract available
     
     
     
122. MARTIN M, Yoder R, Salgado R, Del Monte-Millan M, et al
     Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy.
     Clin Cancer Res. 2024 Mar 11. doi: 10.1158/1078-0432.CCR-24-0106.
     PubMed     Abstract available
     
     
     October 2023
123. PASCUAL J, Gil-Gil M, Proszek P, Zielinski C, et al
     Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
     Clin Cancer Res. 2023;29:4166-4177.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum